• Home >
  • Production

    • Scale-Up

    Pharma companies can’t commercialize their products without scaling up manufacturing. Here, we offer insights on this complicated process and explore the issues surrounding how companies take laboratory-scale batches used in clinical trials to pilot-scale and then finally, to commercial-scale production.

    Articles

    IMG-5103-copy
    Germfree Labs’ city-by-city educational series addresses challenges and solutions in CGT manufacturing
    PM2202-HERO-575x327-CoverStory3
    How one CDMO's dedication to technology is making a global impact
    PM2112-HERO-575x327-Operations
    How off-the-shelf T-cell platforms can make manufacturing CAR-T therapies more feasible and scalable
    PM2111-HERO-575x327-Operations
    Building a CMC strategy for biologics is a critical, multistep process
    PM2110-HERO-575x327-Development
    Commonly overlooked issues may have a deep impact on cell and gene therapy commercialization timelines

    News

    SeptSurveyHERO3
    Overcoming operational challenges in cell and gene therapy production
    Engineering-Aug
    How CDMOs are supporting a paradigm shift in pharma manufacturing
    PM20XX-HERO-575x327-Automation
    Smooth scale-up requires using similar measurement technologies from the lab to full production
    AZ343-Gartuna-Sodertalje-Sweden-aerial-view-copy
    Known for its R&D innovation, Sweden’s pharma industry sets out to prove its manufacturing prowess to the world
    Screen-Shot-2021-02-10-at-12.32.49-AM
    The Center for Breakthrough Medicines is poised to come online as the world's largest single-site CDMO for cell and gene therapies
    Screen-Shot-2021-02-08-at-3.08.54-PM
    Emergent BioSolutions' contract and development manufacturing business has put it at the epicenter of biodefense
    Picture5
    Assessment methods along the product development journey have to be extensive and rigorous to achieve successful scale-up